Skip to main content

Table 3 Relation of Lp(a) levels with composite and separate recurrent CVEs in patients with T2DM

From: Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study

Endpoints Recurrent CVEs/Total Crude model Adjusted model
HR (95% CI) p value HR (95% CI) p value
Composite recurrent CVEs 153/2284     
 Lp(a) per-SD increase   1.007 (1.002–1.013) 0.007 1.008 (1.002–1.014) 0.006
 Lp(a) < 10 37/846 Reference   Reference  
 10 ≤ Lp(a) < 30 59/769 1.736 (1.151–2.619) 0.009 1.720 (1.099–2.692) 0.018
 Lp(a) ≥ 30 57/669 1.960 (1.296–2.965) 0.001 2.049 (1.308–3.212) 0.002
Non-fatal MI 30/2284     
 Lp(a) per-SD increase   1.012 (1.001–1.023) 0.039 1.012 (1.000–1.024) 0.050
 Lp(a) < 10 7/846 Reference   Reference  
 10 ≤ Lp(a) < 30 8/769 1.259 (0.457–3.472) 0.656 1.539 (0.529–4.474) 0.428
 Lp(a) ≥ 30 15/669 2.737 (1.116–6.714) 0.028 3.016 (1.144–7.949) 0.026
Stroke 55/2284     
 Lp(a) per-SD increase   1.002 (0.992–1.011) 0.761 1.001 (0.990–1.012) 0.815
 Lp(a) < 10 17/846 Reference   Reference  
 10 ≤ Lp(a) < 30 22/769 1.408 (0.748–2.651) 0.289 1.355 (0.674–2.724) 0.394
 Lp(a) ≥ 30 16/669 1.199 (0.606–2.372) 0.603 1.118 (0.518–2.413) 0.777
CVD deaths 68/2284     
 Lp(a) per-SD increase   1.009 (1.002–1.017) 0.019 1.011 (1.003–1.020) 0.011
 Lp(a) < 10 13/846 Reference   Reference  
 10 ≤ Lp(a) < 30 29/769 2.419 (1.257–4.652) 0.008 2.242 (1.108–4.535) 0.025
 Lp(a) ≥ 30 26/669 2.539 (1.305–4.942) 0.006 2.708 (1.340–5.475) 0.006
  1. The adjusted model including age, sex, body mass index, current smoking, hypertension, dyslipidemia, family history of coronary artery disease, diseased vessels, low-density lipoprotein cholesterol, fasting blood glucose, statin and anti-diabetes drugs use
  2. CVEs cardiovascular events, MI myocardial infarction, CVD cardiovascular disease